All the news Showing 10 of 34 articles from: Non-nucleoside Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® AbbVie press release / 02 December 2015 European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C AbbVie press release / 16 January 2015 CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe AbbVie press release / 21 November 2014 Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis Liz Highleyman / 11 November 2014 A 12-week all-oral regimen of daclatasvir, asunaprevir and beclabuvir, with or without ribavirin, cured 86 to 90% of genotype 1 hepatitis C patients with cirrhosis in the phase 3 UNITY-2 trial, while the ... AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials HIVandHepatitis.com / 15 September 2014 AbbVie 3D regimen cures most genotype 1 HCV in people with HIV and HCV co-infection Liz Highleyman / 28 July 2014 An oral regimen of three direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people with both HIV and genotype 1 hepatitis C co-infection ... Interferon-free hepatitis C treatment works for people on methadone or buprenorphine Liz Highleyman / 28 July 2014 People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a ... Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence Keith Alcorn / 23 April 2014 A three-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C in a small phase II study reported at ... AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C AbbVie press release / 23 April 2014 AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis Keith Alcorn / 22 April 2014 The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to cure between 92 and 96% ... ← First123...4Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive